All In Biotech

Drug Trial Radar · NCT00000727

A Controlled Comparative Trial of Sulfamethoxazole-Trimethoprim Versus Aerosolized Pentamidine for Secondary Prophylaxis of Pneumocystis Carinii Pneumonia in AIDS Patients Receiving Azidothymidine (AZT)

A Controlled Comparative Trial of Trimethoprim - Sulfamethoxazole Versus Aerosolized Pentamidine for Secondary Prophylaxis of Pneumocystis Carinii Pneumonia in AIDS Patients Receiving Azidothymidine (AZT)

Last checked: Nov 19, 2026Latest source record: Nov 3, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

322

Actual

Start

Not stated

Primary completion

Not stated

Study completion Aug 1991

Sponsor

Sponsor type
NIH
First posted
Aug 31, 2001

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Model
Parallel
Primary purpose
Treatment
Who can join
All sexes, from 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To determine if the drug combination sulfamethoxazole-trimethoprim (SMX-TMP), given by mouth, and the drug pentamidine (PEN), given by inhaled aerosol, are effective in preventing a relapse of Pneumocystis carinii pneumonia (PCP) when they are given to patients who have recovered from a first episode of PCP and are being given zidovudine (AZT) to treat primary HIV infection. AZT prolongs survival in patients with AIDS and decreases the occurrence of opportunistic infections such as PCP. However, PCP recurs in about 43 percent of patients receiving AZT, indicating a need for other treatments to reduce the relapse rate. The two medications to be tested in this study, SMX/TMP and aerosolized PEN, have also been partially effective in preventing recurrence of PCP. It is hoped that the combination of AZT with these medications will be more effective than AZT or one of the medications alone.

Conditions

  • Pneumonia, Pneumocystis Carinii
  • HIV Infections

Interventions

  • Pentamidine isethionateDrug

  • PyrimethamineDrug

  • Sulfamethoxazole/TrimethoprimDrug

  • Sulfadoxine/PyrimethamineDrug

  • ZidovudineDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

No primary outcomes listed.

Locations

9 sites in 1 country. Site status is shown where the registry gives one.

  • USC CRS

    Los Angeles, California

  • Ucsd, Avrc Crs

    San Diego, California

  • Ucsf Aids Crs

    San Francisco, California

  • Indiana Univ. School of Medicine, Infectious Disease Research Clinic

    Indianapolis, Indiana

  • Bmc Actg Crs

    Boston, Massachusetts

  • University of Minnesota, ACTU

    Minneapolis, Minnesota

  • Memorial Sloan-Kettering Cancer Ctr.

    New York, New York

  • Case CRS

    Cleveland, Ohio

  • University of Washington AIDS CRS

    Seattle, Washington

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.